Psoriasis Mouse Model (IL-23-induced)
Perform quick efficacy tests to evaluate your novel psoriasis treatment strategies using the acute psoriasis mouse model
Preclinical psoriasis mouse models are essential tools for understanding the pathogenesis of psoriasis and evaluating the efficacy of novel therapeutic approaches ranging from topical to systemic treatments. Acute models, such as the IL-23 and Imiquimod-induced models, rapidly induce psoriasis-like symptoms, while chronic models mimic the long-term progression of the disease.
The acute psoriasis model, created by intradermal ear injections of recombinant IL-23, leads to acute skin inflammation. IL-23, a key cytokine, promotes pathogenic lymphocytes that drive keratinocyte differentiation and inflammation, hallmarks of psoriasis. This model mimics human psoriasis features, such as inflammatory cell infiltration, epidermal hyperplasia, and activation of inflammatory pathways.
As a preclinical immunology CRO, InnoSer offers relevant expertise to support various skin inflammation studies including psoriasis, atopic dermatitis, contact dermatitis, and scleroderma research. In accordance, our dermatological platform allows us to investigate the efficacy of your novel investigational compound(s) in similar models, including Imiquimod-induced psoriasis, Ovalbumin or Oxazole-induced atopic dermatitis, and the Bleomycin-induced scleroderma model.
Take advantage of InnoSer’s collaborative approach to develop the most optimal study design. With flexible and fast study start times you can perform your research at an accelerated pace. By outsourcing your preclinical oncology studies to InnoSer, you gain access to our in vitro and in vivo immunology drug development portfolio.
Key characteristics of the Il-23-induced mouse model of psoriasis:
- Rapid induction of psoriasis-like symptoms.
- Phenotype exhibits key psoriasis hallmarks, including inflammatory cell infiltration and epidermal hyperplasia.
- Suitable for testing IL-23 inhibitors and other modulators of the IL-23-induced inflammation pathway.
Key readouts in the IL-23 induced psoriasis mouse model:
Test the efficacy of your treatments in the IL-23 induced psoriasis mouse model with the following readouts:
- Body weight determination, clinical observations
- Measurement of ear thickness (assessment of swelling)
- Blood collection for PK/PD analyses
- Biomarker analyses
- Histopathology (to determine the extent and presence of acanthosis, inflammatory cell infiltration, spongiosis, perivascular lymphocyte infiltration, vesicles and pustules, formation, and hyper -granulosis)
- Immunohistochemistry (e.g., FoxP3, CD34)
- Immune cell profiling (MSD, ELISA, flow cytometry, qPCR)
- Inflammatory cytokine analysis via MSD or ELISA
Example data featuring the psoriasis mouse model:
The IL-23 induced psoriasis mouse model represents a translationally relevant model of psoriasis, while allowing you to obtain quick efficacy data.
8-weeks old C57BL6/J mice were injected with recombinant IL-23 in right ear and with PBS (serving as within-subject control) in left ear every two days for a total of 8 days. Mice were dosed with vehicle, test treatment and positive control twice daily via oral gavage. Ear thickness increased in the IL-23 control (vehicle) group following IL-23 injection. A slight decrease in ear thickness was observed on days 4 and 6 in the positive control-treated group.
The IL-23 induced psoriasis mouse model represents a translationally relevant model of psoriasis, while allowing you to obtain quick efficacy data.
Scoring of psoriasis-like lesions following histopathology assessment reveals increase in inflammatory cell infiltration and hypergranulosis in response to IL-23 treatment. Score 0 indicates presence of such features in normal limits, while scores 2 and 3 indicate slight to moderate presence of psoriasis-like features in the tissue. Bars represent M ± SD.
The IL-23 induced psoriasis mouse model represents a translationally relevant model of psoriasis, while allowing you to obtain quick efficacy data.
H&E-stained sections of ear skin confirm psoriasis-like lesions in the IL-23 induced psoriasis mouse model. Vehicle-treated ear sections show spongiosis.
Related model options
Immunology Models Overview
Perform initial screening tests using InnoSer’s in vitro immunoassays to select your lead candidate compounds and progress to in vivo studies with confidence.
mRNA/RNA Therapies
Vaccine Testing and mRNA/RNA therapies: LNP delivery, in vitro assays, biodistribution, PKPD, immunogenicity, dose optimization and more
DTH Mouse Model
Evaluate your compound’s immunomodulatory or immunosuppressive potential in the delayed-type hypersensitivity (DTH) mouse model.
AAALAC Accreditation
InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Our accreditation is valid for three years, incl. 2023. Read more about the AAALAC accreditation programme here.